Patents by Inventor Mark Blaskovich

Mark Blaskovich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11279733
    Abstract: There is provided a range of novel compounds. These novel compounds may demonstrate abroad spectrum antibacterial and antifungal activity. These compounds may be active against the emerging polymyxin resistant bacteria. These compounds may also be useful when used in conjunction with other pharmaceutically active agents.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: March 22, 2022
    Assignee: THE UNIVERSITY OF QUEENSLAND
    Inventors: Matthew Cooper, Mark Blaskovich, Alejandra Gallardo-Godoy, Karl Hansford, Alysha Elliott, Craig Muldoon, Bernd Becker
  • Patent number: 10947271
    Abstract: The invention concerns agents with antibacterial activity, their production and use in the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure X—W-L-V, wherein X is hydrogen, acetyl or a lipophilic membrane-insertive element, W is a basic peptide or basic amino acid; L is a linking group and V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: March 16, 2021
    Assignee: THE UNIVERSITY OF QUEENSLAND
    Inventors: Matthew Cooper, Mark Blaskovich
  • Publication number: 20200078466
    Abstract: A construct comprising: (i) an optionally derivatized glycopeptide antibiotic; (ii) a nanoparticle; and (iii) a first linker connecting (i) and (ii) is provided. The construct may further comprise a second linker located between the first linker and (ii). The nanoparticle may be a separation nanoparticle, such as a magnetic separation nanoparticle. The glycopeptide antibiotic may be selected from the group consisting: of vancomycin; teicoplanin; oritavancin; telavancin; chloroeremomycin; and balhimycin. Also provided are related methods of producing and using the construct, such as methods of separation of bacteria from a sample by binding the bacteria to the construct.
    Type: Application
    Filed: December 11, 2017
    Publication date: March 12, 2020
    Inventors: Mark BLASKOVICH, Matt COOPER, Andrea RANZONI, Wanida PHETSANG, Marwa HASSAN
  • Publication number: 20170204138
    Abstract: The invention concerns agents with antibacterial activity, their production and use in the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure X—W-L-V, wherein X is hydrogen, acetyl or a lipophilic membrane-insertive element, W is a basic peptide or basic amino acid; L is a linking group and V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria.
    Type: Application
    Filed: February 10, 2014
    Publication date: July 20, 2017
    Inventors: Matthew Cooper, Mark Blaskovich
  • Publication number: 20060142250
    Abstract: The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and/or conditions in which the PTP1B enzyme is a factor. Such diseases and/or conditions include, but are not limited to, Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance, insulin resistance, obesity, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, atherosclerosis, vascular restenosis, inflammatory bowel disease, pancreatitis, adipose cell tumors, adipose cell carcinoma, liposarcoma, dyslipidemia, cancer, and neurodegenerative diseases.
    Type: Application
    Filed: November 15, 2005
    Publication date: June 29, 2006
    Inventors: Mark Blaskovich, Ted Baughman, Thomas Little, William Patt, Maher Qabar, Lauri Schultz, Feng Hong, Gangadhar Nagula, Jennifer Gage, James Howbert
  • Patent number: 7053214
    Abstract: Compounds having the following structure: including pharmaceutically acceptable salts and stereoisomers thereof, wherein A, A?, B, X, Y, R2, R3, R4 and R5 are as defined herein. Such compounds have utility over a wide range of applications, including use as diagnostic and therapeutic agents. In particular, compounds of this invention, and pharmaceutical compositions containing such compounds, are tryptase antagonists.
    Type: Grant
    Filed: February 14, 2003
    Date of Patent: May 30, 2006
    Assignee: Myriad Genetics, Inc.
    Inventors: Cyprian O. Ogbu, Hwa-Ok Kim, Mark A Blaskovich
  • Publication number: 20060084653
    Abstract: Compounds having the following structure: including pharmaceutically acceptable salts and stereoisomers thereof, wherein A, A?, B, X, Y, R2, R3, R4 and R5 are as defined herein. Such compounds have utility over a wide range of applications, including use as diagnostic and therapeutic agents. In particular, compounds of this invention, and pharmaceutical compositions containing such compounds, are tryptase antagonists.
    Type: Application
    Filed: December 6, 2005
    Publication date: April 20, 2006
    Applicant: Myriad Genetics, Incorporated
    Inventors: Cyprian Ogbu, Hwa-Ok Kim, Mark Blaskovich
  • Publication number: 20040014763
    Abstract: Compounds having the following structure: 1
    Type: Application
    Filed: February 14, 2003
    Publication date: January 22, 2004
    Applicant: Myriad Pharmaceuticals, Inc.
    Inventors: Cyprian O. Ogbu, Hwa-Ok Kim, Mark A. Blaskovich